<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67161">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01940939</url>
  </required_header>
  <id_info>
    <org_study_id>11ZR1431600</org_study_id>
    <nct_id>NCT01940939</nct_id>
  </id_info>
  <brief_title>A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation for the Treatment of Cognitive Impairment Such as Working Memory in Schizophrenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Exploration of rTMS on working memory and cognitive impairment symptoms of
           schizophrenia treatment and mechanism.

        2. Analysis of rTMS high-frequency stimulation to the improvement of negative symptoms and
           psychotic symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Performance on the N-back working memory task and MATRICS Consensus Cognitive Battery（MCCB）</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>gamma power and ITC (inter-trial coherence) changes</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an intertrain interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <arm_group_label>Active rTMS</arm_group_label>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1）patients to be diaginsed according to DSM-IV for paranoid schizophrenia；2）20～49
             years old；3）Duration of 2 ~ 10 years;4）the disease situation is stable， the
             fluctuation of PANSS total score ≤10% in last 1 month, and have accepted the current
             drugs for more than 8 weeks; 5）Patients, their families and doctors are agreed that
             the disease situation is stable and maintainthe current drug treatmentdrug  in next
             month；6）Signed an informed consent

        Exclusion Criteria:

          -  1)patients to be diaginsed according to DSM-IV for substance abused,development
             delayed;2)suffering from serious physical disease and can not accept the
             treatment;3)rTMS contraindications: intracranial metal substance, with heart
             pacemakers and cochlear implants, intracranial pressure;4)the disease situation is
             not stable， the fluctuation of PANSS total score &gt;10% in last 1 month, PANSS total
             score &gt; 60;5)difficult to maintain the current drug treatment for at least 1
             month;6）undergoing ECT or MECT in last 3 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dengtang Liu, MD</last_name>
    <phone>+862164387250-73775</phone>
    <phone_ext>+862164387986</phone_ext>
    <email>erliu110@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dengtang Liu, MD</last_name>
      <phone>+862164387250-73775</phone>
      <email>erliu110@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
